国际流行病学传染病学杂志
國際流行病學傳染病學雜誌
국제류행병학전염병학잡지
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY AND INFECTIOUS DISEASE
2008年
3期
164-166
,共3页
李力鸿%刘雪峰%张长%颜呜鹤%黄希田
李力鴻%劉雪峰%張長%顏嗚鶴%黃希田
리력홍%류설봉%장장%안오학%황희전
肝炎,乙型,慢性%恩替卡韦%疗效
肝炎,乙型,慢性%恩替卡韋%療效
간염,을형,만성%은체잡위%료효
Hepatiti B,chronic%Entecavir%Curative efficacy
目的 探讨恩替卡韦对33例乙型肝炎(乙肝)的治疗效果.方法 应用恩替卡韦0.5 mg/d口服治疗33例乙肝患者,其中慢性携带者7例,慢性轻度患者12例,慢性中度患者14例.主要检测血清HBV DNA水平,与基线值相比的平均下降量,HBV DNA阴转率(<3log10拷贝/ml);并同时检测ALT、AST复常率.结果 三组患者HBV DNA水平随治疗时间延长呈进行性下降,与基线相比的平均下降量也相应逐渐增加,三组两两比较差异无统计学意义.治疗24周后,携带者HBV DNA阴转率为57.1%,轻度患者为75.0%,中度患者为100.0%.其中,中度患者在治疗至12周、24周、36周时,HBV DNA阴转率显著高于携带者(P<0.05),仅在12周时HBV DNA阴转率高于轻度患者(P<0.01).中度患者48周时有5例达血清转换(35.7%),轻度患者在48周时有4例达血清转换(33.3%).轻度、中度患者分别在36周、24周时ALT/AST完全复常.结论 恩替卡韦治疗乙肝有较高疗效,安全,耐药风险低,值得推广.
目的 探討恩替卡韋對33例乙型肝炎(乙肝)的治療效果.方法 應用恩替卡韋0.5 mg/d口服治療33例乙肝患者,其中慢性攜帶者7例,慢性輕度患者12例,慢性中度患者14例.主要檢測血清HBV DNA水平,與基線值相比的平均下降量,HBV DNA陰轉率(<3log10拷貝/ml);併同時檢測ALT、AST複常率.結果 三組患者HBV DNA水平隨治療時間延長呈進行性下降,與基線相比的平均下降量也相應逐漸增加,三組兩兩比較差異無統計學意義.治療24週後,攜帶者HBV DNA陰轉率為57.1%,輕度患者為75.0%,中度患者為100.0%.其中,中度患者在治療至12週、24週、36週時,HBV DNA陰轉率顯著高于攜帶者(P<0.05),僅在12週時HBV DNA陰轉率高于輕度患者(P<0.01).中度患者48週時有5例達血清轉換(35.7%),輕度患者在48週時有4例達血清轉換(33.3%).輕度、中度患者分彆在36週、24週時ALT/AST完全複常.結論 恩替卡韋治療乙肝有較高療效,安全,耐藥風險低,值得推廣.
목적 탐토은체잡위대33례을형간염(을간)적치료효과.방법 응용은체잡위0.5 mg/d구복치료33례을간환자,기중만성휴대자7례,만성경도환자12례,만성중도환자14례.주요검측혈청HBV DNA수평,여기선치상비적평균하강량,HBV DNA음전솔(<3log10고패/ml);병동시검측ALT、AST복상솔.결과 삼조환자HBV DNA수평수치료시간연장정진행성하강,여기선상비적평균하강량야상응축점증가,삼조량량비교차이무통계학의의.치료24주후,휴대자HBV DNA음전솔위57.1%,경도환자위75.0%,중도환자위100.0%.기중,중도환자재치료지12주、24주、36주시,HBV DNA음전솔현저고우휴대자(P<0.05),부재12주시HBV DNA음전솔고우경도환자(P<0.01).중도환자48주시유5례체혈청전환(35.7%),경도환자재48주시유4례체혈청전환(33.3%).경도、중도환자분별재36주、24주시ALT/AST완전복상.결론 은체잡위치료을간유교고료효,안전,내약풍험저,치득추엄.
Objective To evaluate the curative efficacy in patients with chronic hepatitis B(CHB)treated with eraecavir(ETV).Method 33 patients with CHB(7 HBV-chronic carriers,12 mild cases and 14 moderate cases)were treated with entecavir 0.5 mg/d and detected serum HBV DNA,ALT,AST level and HBeAg seroconversion.Results Serum HBV DNA levels of 3 groups were dropped gradually with the therapy.The average declining counts compared with the baseline were increased too.There were no significant differences in the 3 groups compared with each other.At week 24 after treatment,the rates of HBV DNA reduced to negative were 57.1%,75.0%and 100.0%in HBV-chronic carriers group,mild group and moderate group respectively.The rates of HBV DNA reduced to negative in moderate group were higher than that of in HBV-chronic carriers group at 12,24,36 weeks(P<0.05).The rate of HBV DNA reduced to negative in moderate group was higher than that of in mild group at 12 weeks only(P<0.01).5 cases(35.7%)procured HBeAg seroconversion at 48 weeks in moderate group.4 cases(33.3%)procured HBeAg seroconversion at 48 weeks in mild group.ALT/AST recovered to normal in mild group at 36 weeks,in moderate group at 24 weeks respectively.Conclusions ETV is efficacy and safety in patients with chronic hepatitia B.
